


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I), or an enantiomer or diastereoisomer thereof, or a salt, hydrate or solvate thereof:



wherein Ar represents an optionally substituted ~~phenylaryl, heteroaryl, C₃-C₆ cycloalkyl or heterocycloalkyl~~ group;

R represents hydrogen or C₁-C₆ alkyl, or C₃-C₆ cycloalkyl;

Alk represents a divalent C₁-C₅ alkylene or C₂-C₅ alkenylene radical; and

~~R₁ and R₂ taken together with the nitrogen atom to which they are attached form a piperazinyl ring—first heterocycloalkyl ring which is optionally fused to a second C₃-C₆ cycloalkyl or heterocycloalkyl ring, the said first and second rings being~~ optionally substituted by at least one group of formula (II):



wherein m, p and n are independently 0 or 1;

Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or

heterocyclic ring of from 5 to 7 ring atoms;

Alk¹ and Alk² independently represent optionally substituted divalent C₁-C₃ alkylene radicals;

X represents -O-, -S-, -S(O)-, -S(O)₂-, -C(=O)-, -NH-, -NR₃-,
-S(O₂)NH-, -S(O₂)NR₃-, -NHS(O₂)-, or -NR₃S(O₂)-, where R₃ is C₁-C₃ alkyl.

2. (Original) A compound as claimed in claim 1 wherein R is hydrogen.
3. (Original) A compound as claimed in claim 1 wherein R is methyl.
4. (Original) A compound as claimed in claim 1 wherein R is ethyl, n-propyl, isopropyl, n-, sec- or tert-butyl, cyclopropyl, or cyclopentyl.
5. (Currently Amended) A compound as claimed in Claim 1 wherein Ar is a ~~5- or 6-~~ membered monocyclic aryl or heteroaryl ring, which is optionally substituted by at least one substituent selected from (C₁-C₃)alkyl, (C₁-C₃)alkoxy, hydroxy, hydroxy(C₁-C₃)alkyl, mercapto, mercapto(C₁-C₃)alkyl, (C₁-C₃)alkylthio, halo, trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), -COOH, -COOR^A, -COR^A, -SO₂R^A, -CONH₂, -SO₂NH₂, -CONHR^A, -SO₂NHR^A, -CONR^AR^B, -SO₂NR^AR^B, -NH₂, -NHR^A, -NR^AR^B, -OCONH₂, -OCONHR^A, -OCONR^AR^B, -NHCOR^A, -NHCOOR^A, -NR^BCOOR^A, -NHSO₂OR^A, -NR^BSO₂OR^A, -NHCONH₂, -NR^ACONH₂, -NHCONHR^B, -NR^ACONHR^B, NHCONR^AR^B, or -NR^ACONR^AR^B wherein R^A and R^B are independently C₁-C₃ alkyl, phenyl or a 5- or 6-membered monocyclic aryl or heteroaryl ring.
6. (Currently Amended) A compound as claimed in claim 5 wherein the phenyl ring is an optional substituent is substituted in the 4- position in the case of a 6-membered ring, or in the 2- and/or 3- position in the case of a 5-membered ring.
7. (Canceled)
8. (Previously Presented) A compound as claimed in Claim 1 wherein optional substituents

in Ar are selected from methoxy, ethoxy, trifluoromethoxy, methyl, ethyl, trifluoromethyl, hydroxyl, mercapto, fluoro, chloro, and bromo.

9. (Original) A compound as claimed in claim ~~5~~1 wherein Ar is 4-(C₁C₃alkoxy)phenyl.

10. (Previously Presented) A compound as claimed in claim ~~5~~1 wherein Ar is 4-ethoxyphenyl.

11. (Previously Presented) A compound as claimed in Claim 1 wherein Alk is -CH₂-, -CH₂CH₂-, -CH₂CH(CH₃)-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH=CH-, -CH₂CH=CH-, -CH₂CH=CHCH₂-, or -CH=CHCH=CH-.

12. (Canceled)

13. (Canceled)

14. (Previously Presented) A compound as claimed in Claim 1 wherein in the group (II), when present, p is 0, Z is hydrogen and at least one of n and m is 1.


15. (Previously Presented) A compound as claimed in Claim 1 wherein in the group (II), when present, m, n and p are all 0 and Z is a carbocyclic or heterocyclic ring directly linked to a ring carbon or ring nitrogen of the -NR₁R₂ group.

16. (Previously Presented) A compound as claimed in Claim 1 wherein in the group (II), when present, p is 0, at least one of m and n is 1, and Z is a carbocyclic or heterocyclic ring linked to a ring carbon or ring nitrogen of the -NR₁R₂ group via a C₁-C₆ alkylene linker between Z and the -NR₁R₂ ring.

17. (Previously Presented) A compound as claimed in Claim 1 wherein in the group (II), when present, p is 1.

18. (Original) A compound as claimed in claim 1 of formula (1B) or (1C) or an enantiomer


or diastereoisomer thereof, or a salt, hydrate or solvate thereof:



wherein R is hydrogen or methoxy, R_3 is trifluoromethyl, trifluoromethoxy C_1 - C_3 alkoxy, hydroxy, or halo; R_4 is (i) $-SO_2R_5$ or $-COR_5$ wherein R_5 is C_1 - C_6 alkyl or phenyl or monocyclic heteroaryl having 5 or 6 ring atoms, optionally substituted by (C_1 - C_3)alkyl, (C_1 - C_3)alkoxy, hydroxy, hydroxy(C_1 - C_3)alkyl, mercapto, mercapto(C_1 - C_3)alkyl, (C_1 - C_3)alkylthio, halo, trifluoromethyl, trifluoromethoxy or (ii) phenyl or monocyclic heteroaryl having 5 or 6 ring atoms; optionally substituted by (C_1 - C_3)alkyl, (C_1 - C_3)alkoxy, hydroxy, hydroxy(C_1 - C_3)alkyl, mercapto, mercapto(C_1 - C_3)alkyl, (C_1 - C_3)alkylthio, halo, trifluoromethyl, trifluoromethoxy.

19. (Original) A compound as claimed in claim 18 wherein a heteroaryl ring forming part of R_4 is pyridyl, pyrimidinyl, triazinyl, thienyl, or furanyl.

20. (Previously Presented) A compound as claimed in Claim 1 having the stereochemical configuration shown in formula (IA):



21. (Currently Amended) A compound as claimed in claim 1, which is selected from the group consisting of:

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)-hexanoic acid hydroxyamide;~~

~~3R-(6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-6-(4-ethoxyphenyl)-2S-hydroxy-hexanoic acid hydroxyamide;~~

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-methoxy-phenyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-phenyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-yl-piperazine-1-carbonyl)-hexanoic acid hydroxyamide;

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2RS-methyl-morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(2,6-RS-dimethyl-morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(thiomorpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~3R-(4-benzyl-piperidine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid
hydroxyamide;~~

3R-(4-benzo[1,3]dioxol-5-ylmethyl-piperazine-1-carbonyl)-6-(4-ethoxyphenyl)-2S-hydroxy-
hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-4-ylmethyl-piperazine-1-carbonyl)-hexanoic
acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-benzylpiperazine-1-carbonyl)-hexanoic acid
hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(4-pyrimidin-2-yl-piperazine-1-carbonyl)-hexanoic acid
hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethyl-pyrimidin-2-yl)-piperazine-1-
carbonyl]-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-chloro-pyrimidin-2-yl)-piperazine-1-carbonyl]-
hexanoic acid hydroxyamide;

3R-[4-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-piperazine-1-carbonyl]-6-(4-ethoxyphenyl)-2S-
hydroxy-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(3-trifluoromethyl-phenyl)-piperazine-1-carbonyl]-
hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-hexanoic
acid hydroxyamide;

~~3R-[4-(acetyl-methyl-amino)-piperidine-1-carbonyl]-6-(4-ethoxy-phenyl)-2S-hydroxy-
hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(methyl-propyl-amino)-piperidine-1-carbonyl]-~~

~~hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-benzyl-morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-isobutyl-morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~6-(4-ethoxy-phenyl)-2S-hydroxy-3R-(3S-phenyl-morpholine-4-carbonyl)-hexanoic acid hydroxyamide;~~

~~3R-(4-benzyl-3RS-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;~~

~~3R-(3S,4-dibenzyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxyhexanoic acid hydroxyamide;~~

~~3R-(4-benzyl-3RS-phenyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;~~

~~4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-2S, N-dihydroxy-4-oxo-3R-(4-trifluoromethoxy-benzyl)-butyramide;~~

~~3R-benzyl-2S, N-dihydroxy-4-morpholin-4-yl-4-oxo-butylamide;~~

~~3R-(4-benzyloxy-benzyl)-2S, N-dihydroxy-4-oxo-4-piperidin-1-yl-butylamide;~~

~~2S, N-dihydroxy-3R-(4-hydroxy-benzyl)-4-oxo-4-piperidin-1-yl-butylamide;~~

~~4-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3R-(4-benzyloxy-benzyl)2S, N-dihydroxy-4-oxo-butylamide;~~

~~6-(3, 5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(morpholine-4-carbonyl)hexanoic acid hydroxyamide;~~

~~3R-(4-benzyl-piperidine-1-carbonyl)-6-(3,5-bis-trifluoromethyl-phenyl)-2S-hydroxy-hexanoic acid hydroxyamid;~~

6-(3, 5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)-hexanoic acid hydroxyamide;

~~6-(3, 5-bis-trifluoromethyl-phenyl)-3R-(6, 7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-2S-hydroxy-hexanoic acid hydroxyamide;~~

~~6-(3, 5-bis-trifluoromethyl-phenyl)-2S-hydroxy-3R-(pyrrolidine-1-carbonyl)-hexanoic acid hydroxyamide~~

3R-(2S-benzyl-4-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2Shydroxy-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-trifluoromethoxy-benzenesulfonyl)piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(toluene-4-sulfonyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

3R-[4-(5-bromo-thiophene-2-sulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxyphenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-[4-(5-benzenesulfonyl-thiophene-2-sulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-[4-(4-butoxy-benzenesulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxy-phenyl)2S-hydroxy-hexanoic acid hydroxyamide;

6-(4-ethoxy-phenyl)-2S-hydroxy-3R-[4-(4-methoxy-2,3, 6-trimethylbenzenesulfonyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

3R-[4-(3,4-dimethoxy-benzenesulfonyl)-piperazine-1-carbonyl]-6-(4-ethoxyphenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

6-(4-methoxy-phenyl)-2S-hydroxy-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide;

6-(4-methoxy-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)-hexanoic acid hydroxyamide;

6-(4-fluoro-phenyl)-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-2S-hydroxy-hexanoic acid hydroxyamide;

6-(4-fluoro-phenyl)-2S-hydroxy-3R-(4-pyridin-2-yl-piperazine-1-carbonyl)-hexanoic acid hydroxyamide;

3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-ethoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-(4-benzyl-2S-i-butyl-piperazine-1-carbonyl)-6-(4-methoxy-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-(4-benzyl-2S-methyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyl)-2S-hydroxy-hexanoic acid hydroxyamide;

3R-(4-benzyl-2S-i-butyl-piperazine-1-carbonyl)-6-(4-fluoro-phenyl)-2S-hydroxy-hexanoic

acid hydroxyamide;

4-[5-(4-ethoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-methyl-piperazine-1-carboxylic acid tert-butyl ester;

4-[5-(4-ethoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-i-butyl-piperazine-1-carboxylic acid tert-butyl ester;

4-[5-(4-methoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-methyl-piperazine-1-carboxylic acid tert-butyl ester;

4-[5-(4-methoxy-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-i-butyl-piperazine-1-carboxylic acid tert-butyl ester;

4-[5-(4-fluoro-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-methyl-piperazine-1-carboxylic acid tert-butyl ester.

4-[5-(4-fluoro-phenyl)-2R-(1S-hydroxy-hydroxycarbamoyl-methyl)-pentanoyl]-2S-i-butyl-piperazine-1-carboxylic acid tert-butyl ester; and

6-(4-ethoxy-phenyl)-2S-methoxy-3R-[4-(2-fluoro-phenyl)-piperazine-1-carbonyl]-hexanoic acid hydroxyamide.

22. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in Claim 1, together with a pharmaceutically acceptable carrier.

23. (Canceled)

24. (Previously Presented) A method of treatment or prophylaxis of ~~diseases or conditions responsive to inhibition of MMP-12 and/or MMP-9~~ arthritis in mammals, which method comprises administering to the mammal an effective amount of a compound as claimed in Claim 1.

25. (Canceled)

26. (Previously Presented) A method as claimed in claim 24 wherein the disease or condition is bone resorption, tumour growth or invasion by secondary metastases; arthritis is selected from rheumatoid arthritis, septic arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, cardiac hypertrophy, acute respiratory distress syndrome, neuroinflammatory disorders, e.g. multiple sclerosis, restenosis, emphysema, fibrotic disease e.g. fibrosis post radiotherapy, kerotid scarring, liver fibrosis and cystic fibrosis; chronic obstructive pulmonary disease; bronchitis; asthma; autoimmune disease; transplant rejection (e.g. graft versus host disease); cystic fibrosis; psoriasis; or psoriatic arthritis; degenerative cartilage loss; inflammatory gastric conditions, e.g. Crohn's disease, inflammatory bowel disease, and ulcerative colitis; atopic dermatitis, epidermolysis bullosa; epidermic ulceration; a neuropathy or nephropathy e.g. interstitial nephritis, glomerulonephritis or renal failure; ocular inflammation; liver cirrhosis, Sjogren's syndrome; or an inflammatory condition of the nervous system.

Claims 27-30 (Canceled)